Thiazole-based inhibitors of scavenger receptor BI
This application describes compounds and methods that can inhibit Scavenger receptor class B, type I (SR-BI) activity, which compounds and methods can used, for example, to mediate high-density lipoprotein (HDL) lipid uptake and treat hepatitis C viral infections.
1. A compound of the formula:
or a salt or solvate thereof.
2. A compound of the formula:
or a salt or solvate thereof.
3. A method of inhibiting Scavenger receptor class B, type I (SR-BI) lipid transport activity comprising exposing said receptor to a compound of the formula
or a salt or solvate thereof.
4. A method of inhibiting Scavenger receptor class B, type I (SR-BI) lipid transport activity comprising exposing said receptor to a compound of the formula:
or a salt or solvate thereof.
5. The method of claim 3 or 4 , wherein said lipid transport activity is determined by measuring the binding of 125 I-HDL or Alexa-labeled HDL to cells.
6. The method of claim 3 or 4 , wherein said method comprises increasing the strength of binding of high-density lipoprotein (HDL) to cells.
7. The method of claim 3 or 4 , wherein said method comprises inhibiting SR-BI transport of cholesteryl ester or other lipids from high-density lipoprotein (HDL) into cells expressing SR-BI.
8. The method of claim 3 or 4 , wherein said method comprises inhibiting transport of cholesterol or other lipids from cells expressing SR-BI into high-density lipoprotein (HDL).
9. A method of treating a hepatitis C viral infection, comprising administering to a subject in need thereof an effective amount of a compound of the formula:
or a salt or solvate thereof.
10. A method of treating a hepatitis C viral infection, comprising administering to a subject in need thereof an effective amount of a compound of the formula:
or a salt or solvate thereof.